StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Padcev (enfortumab vedotin ADC by Quarter

Padcev (enfortumab vedotin ADC — urothelial cancer, via Seagen) — U.S. reported YoY (%) (%)

Pfizer Padcev (enfortumab vedotin ADC: 21.0% in Q2 2026, down 17.0 pts from a year earlier.

Latest, Q2 2026
21.0%
Period ended Jun 28, 2026
Change on a year earlier
-17.0 pts
38.0% in Q2 2025
History
6 quarters
Since Q1 2025
Sources
6
Documents cited below

Where the Q2 2026 figure comes from

“|| Padcev | 667 | 542 | 23% | 23% | 648 | 534 | 21% | 19 | 7 | * | *”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Cite this data

StockData. (2026). Pfizer Padcev (enfortumab vedotin ADC (%), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/padcev-yoy-us

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.